Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up – Should You Buy?
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up – Still a Buy?
Source link
Similar Posts
D-St rebounds: Rs 6 lakh crore added! Sensex jumps 900 points; Nifty nears 23,300; easing oil prices among 3 key factors
Indian stock markets opened in the green on Friday, as bears took a breather after the massive selloff seen yesterday. Sensex rose more than 900 points, while Nifty jumped over 270 points in the morning, as easing oil prices and other factors pushed markets up. Sensex jumped around 960 points to 75,165, while Nifty 50…
Applied Materials Dividend Increase
On 13 March, Applied Materials (AMAT) increased its dividend by 15.22%, from 46¢ to 53¢ per share. The dividend is payable on 11 June to shareholders of record on 21 May. AMAT’s contribution to DivGro’s projected annual dividend income will increase by $23.80 to $180.20. I own 85 shares of AMAT at an average cost basis of $161.25 per share….
NASA Reports Fuel Leak in Moon Rocket Test Countdown
February 3, 2026February 3, 2026 NASA’s plans for its next crewed moon mission hit a hurdle after a hydrogen fuel leak disrupted a crucial practice countdown for its new moon rocket. As a result, the space agency pushed the launch target to March. The issue…
Fed Vice Chair Jefferson: Slow approach to cuts makes sense as policy rate approaches neutral
The Federal Reserve should “proceed slowly” in approving further interest rate cuts as monetary policy moves closer to a neutral stance, Fed Vice Chair Philip Jefferson said on Friday. Following a quarter-point rate cut last week, which Jefferson supported, he said “the current policy stance is still somewhat restrictive,” and is serving to push down…
Linkfest: 01 August, 2025
Some stuff I am reading today morning: US finalizes Tariff rates (White House) India not to compromise on core interests (BS) Oil markets are now paying attention to Trump’s threats (OP) Indian Pharma braces for Trump’s tariff fallout (Forbes) SC recalls verdict on Bhushan Steel (Rediff) Regulatory overreach by SEBI (ML) The cheap Rs 10…
